KYC

Elvina® - Bioequivalent to Yasmin®

  • Contains 0.03mg ethinylestradiol and 3mg drospirenone, exactly the same active ingredients as Yasmin®¹-²

 

  • Indicated for the prevention of pregnancy in women who elect to use an oral contraceptive¹

 

  • Inhibits ovulation & causes changes in the endometrium¹

 

  • Contains drospirenone which exhibits both antiandrogenic & antimineralocorticoid properties¹

 

  • Drospirenone has a pharmacological profile resembling the natural hormone progesterone¹

 

  • Is highly effective when taken correctly & consistently¹-⁴

 

  • ELVINA® has a Pearl Index of 0.57¹

 

  • Contains soya lecithin - patients with allergies to soya or peanut should not be prescribed ELVINA®1

 

  • ELVINA® is non GMS reimbursed
     

ELVINA® is suitable for use in the following patient groups:⁵-⁶

  • Women who want autonomy and control over their menstrual cycle
  • Women aged up to 50 years with no other medical conditions
  • Women with a BMI of ≤34kg/m2 who do not smoke
  • Women ≥6 months postpartum if fully breast feeding
  • Women ≥6 weeks postpartum if not breast feeding
  • Women with dysmenorrhoea who have an irregular, heavy or prolonged bleeding pattern
  • Women with endometriosis
SPC
PIL
Book an appointment with a Consilient Health Representative
Report an adverse event

 

 



References:

1. Elvina® SmPC
2. Yasmin® SmPC
    available at www.medicines.ie
3. MIMS Ireland (August 2017) 'Contraception' MPI Media Ltd, Dublin.
4. Krattenmacher, R. 2000 Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000 Jul;62(1):29-38.
5. WHO Guidelines. Medical Eligibility Criteria for contraceptive use 2015 update.
6. Faculty of Sexual and Reproductive Health Care (FSRH). UK Medical Eligibility Criteria for Contraceptive Use. UKMEC 2016. London: FSRH, 2016.

Important Information Regarding Cookies and KYC

By using this website, you consent to the use of cookies in accordance with the KYC Cookie Policy. For more information on cookies see our Privacy Policy.